Head of Business Development
Jack Elands
Phone: +44 7947 870 482
jack.elands@sidec.com
Sign up for e-mail notifications of important Sidec news.
(May 01, 2008 07:13 PM)Sidec announced today the first Protein Tomography™ Award. The winning project will obtain a Protein Tomography™ collaboration financed by Sidec. This announcement was made at Sidec’s Executive Forum during the fourth Annual PEGS meeting organized by CHI.
The use of Protein Tomography™ to answer questions related to therapeutic antibody development was presented at Sidec’s Executive Forum. Berkley Lynch, previously Principal Investigator at UCB, spoke about the use of Protein Tomography™ to Image the Synaptic Vesicle of protein 2A in situ and José R. Casas-Finet, Director, R&D and Medical Biochemistry, MedImmune showed how antibody conformations and interactions can be studied by Protein Tomography™. At the Forum, Wim, K. Bleeker, Director Translational Research & Pharmacology at Genmab presented the modes of action of HuMax-EGFr (zalutumumab) published in PNAS April 22nd and how this was determined together with Sidec using Protein Tomography™.
Finally, Kathleen Madden Williams, PhD, JD Edwards Agnell Palmer & Dodge LLP discussed the ever-narrowing tunnel that present day patent protection on antibodies has entered and whether there is a gold standard by which antibodies are distinguishable from one another thereby to enable more meaningful patent protection.
“During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec’s Protein Tomography™ Award fills an important role in encouraging research groups in the biopharmaceutical industry to try a new avenue, such as Protein Tomography™, to increase their chances of success” says Hans Johansson CEO at Sidec AB.